Skip to content

WHEN DO WE HAVE to PERFORM CARDIAC MAGNETIC RESONANCE in PATIENTS REFERRED for PREMATURE VENTRICULAR COMPLEXES by THEIR CARDIOLOGISTS

WHEN DO WE HAVE to PERFORM CARDIAC MAGNETIC RESONANCE in PATIENTS REFERRED for PREMATURE VENTRICULAR COMPLEXES by THEIR CARDIOLOGISTS

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06801743
Acronym
IRMESV
Enrollment
200
Registered
2025-01-30
Start date
2024-11-27
Completion date
2026-05-31
Last updated
2025-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Magnetic Resonance Imaging, Focal or Diffuse Fibrosis, Idiopathic, Premature Ventricular Complexes, Structural Heart Disease, Ventricular Arythmias

Keywords

premature ventricular complexes, ventricular arythmias, cardiac magnetic resonance, focal or diffuse fibrosis, structural heart disease, idiopathic

Brief summary

Premature ventricular complexes (PVC) are a common entity affecting approximatively 20% of the general population. It can be discovered incidentally on electrocardiogram (ECG) or associated with symptoms with a wide spectrum from palpitations, chest pain, to syncope. The initial and non invasive assessment includes holter ECG monitoring, a transthoracic echocardiography (TTE) and an exercise stress test to rule out structural heart disease (SHD), and referred to as benign or idiopathic ventricular arrhythmias (IVA). However, these exams may fail to identify subtle myocardial abnormalities such as arrhythmogenic right ventricle dysplasia (ARVD), apical hypertrophic cardiomyopathy, healed myocarditis, ischemic or non-ischemic cardiomyopathies. Cardiac magnetic resonance (CMR) imaging is the gold standard modality to assess regional and global ventricular function. It is also a unique modality to non-invasively detect myocardial edema, myocardial fatty replacement, focal and diffuse fibrosis and could potentially identify SHD in patients with PVC. However, the role of CMR is uncertain, recommended in case of atypical presentation or when the initial assessment can't exclude a cardiomyopathy (recommendations class IIa). This study sought to determine whether and when CMR can be performed to provide diagnosis or prognostic information complementary to initial assessment in patients referred for PVC by their cardiologists.

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with PVC who have performed ECG, Holter ECG and a CMR

Exclusion criteria

* patient showing opposition tu use his personal data for the reseach, * patient unable to express his opposition, * patient deprived of liberty, * patient with language issues (speaking or writing French)

Design outcomes

Primary

MeasureTime frameDescription
Number of myocardial abnormalities identified by CMR1 dayComposite endpoint of myocardial abnormalities identified by CMR including dilated cardiomyopathy, hypertrophic cardiomyopathy, ischemic cardiomyopathy, ventricular non-compaction, ARVD, myocarditis, pericarditis, sarcoidosis, amyloidosis, Fabry disease

Secondary

MeasureTime frame
number of criteria to predict myocardial abnormalities on CMRday 1

Countries

France

Contacts

Primary ContactEmmanuelle VERMES, MD
vermes.emmanuelle@chu-amiens.fr33 + 322087302

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026